Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccine.
Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccine.
复制标题
DOI：
10.1136/bcr-2021-242678
复制
发表时间：
2021-07-30
期刊：
影响因子：
0.9
通讯作者：
Shams S
中科院分区：
文献类型：
--
作者：
Hines A;Shen JG;Olazagasti C;Shams S
一名26岁的女性在接受Moderna mRNA-1273 SARS-CoV-2疫苗后2周因新的点状皮疹和血小板减少症被初级保健医生送往急诊室。她的住院过程因转氨酶升高而变得复杂。在接受静脉注射类固醇和静脉注射免疫球蛋白治疗疑似免疫性血小板减少性紫癜后，患者的血小板计数在住院第5天恢复正常。对她的血小板减少症和转氨酶升高进行了广泛的检查，结果并不明显，包括排除了感染、自身免疫和毒性原因。肝活检没有发现，她的转氨酶在出院时有所改善。尽管尚未得到证实，但她接种疫苗与血小板减少症和异常肝酶的时间关系表明Moderna mRNA-1273 SARS-CoV-2疫苗是最可能的诱发因素。
A 26-year-old woman was sent to the emergency room by her primary care physician for a new petechial rash and thrombocytopenia 2 weeks after receiving the Moderna mRNA-1273 SARS-CoV-2 vaccine. Her hospital course was complicated by transaminitis. Her platelet count improved to normal on hospital day 5 after receiving intravenous steroids and intravenous immunoglobulin to treat her suspected diagnosis of immune thrombocytopenic purpura. Extensive workup for her thrombocytopenia and transaminitis was unremarkable including ruling out infectious, autoimmune and toxic causes. A liver biopsy was unrevealing and her transaminitis was improved on discharge. Although not proven, the temporal relationship of her vaccination with thrombocytopenia and abnormal liver enzymes points towards the Moderna mRNA-1273 SARS-CoV-2 vaccine as the most likely inciting factor.
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group